Home > Insider Trading > Filing (0001415889-25-008663)

Filing Details

Accession Number:: 0001415889-25-008663
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-03-19 21:35:14
Reporting Period:: 2025-03-17

Filing Date:: 2025-03-19
Accepted Time:: 2025-03-19 21:35:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1604821	Natera Inc.	NTRA	Services-Medical Laboratories (8071)	010894487

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1646649	Jonathan Sheena	C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-17	181	$146.03	261,019	No	4	S	Direct
Common Stock	Disposition	2025-03-18	2,017	$145.17	259,002	No	4	S	Direct
Common Stock	Disposition	2025-03-18	53	$145.60	258,949	No	4	S	Direct
Common Stock	Disposition	2025-03-18	630	$146.81	258,319	No	4	S	Direct
Common Stock	Disposition	2025-03-18	1,070	$145.09	42,212	No	4	S	Indirect	By Caraluna 1 Trust
Common Stock	Disposition	2025-03-18	430	$146.78	41,782	No	4	S	Indirect	By Caraluna 1 Trust
Common Stock	Disposition	2025-03-18	1,010	$145.21	42,272	No	4	S	Indirect	By Caraluna 2 Trust
Common Stock	Disposition	2025-03-18	490	$146.78	41,782	No	4	S	Indirect	By Caraluna 2 Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Caraluna 1 Trust
No	4	S	Indirect	By Caraluna 1 Trust
No	4	S	Indirect	By Caraluna 2 Trust
No	4	S	Indirect	By Caraluna 2 Trust

Footnotes

The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 12, 2025.
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.55 to $145.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.78 to $147.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.55 to $145.43 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.78 to $146.79 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.67 to $145.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.40 to $146.96 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.